HCW Biologics
Business Services · Florida, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
2929 N Commerce Pkwy, Miramar, Florida, ...Phone Number
(954) 842-2024Website
www.hcwbiologics.comRevenue
$6.7 MillionStock Symbol
HCWBIndustry
ZI Rank: 1
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
2
2
1
1
1
1
About HCW Biologics
HCW Biologics is a clinical-stage biopharmaceutical company developing fusion immunotherapeutics for chronic inflammation-driven diseases, including autoimmune disorders, cancer, and senescence-associated dysplasia. Led by Founder/CEO Dr. Hing C. Wong (who previously developed FDA-approved Anktiva®, sold to ImmunityBio for $1.0B), lead candidates HCW9302, HCW11-018b, and HCW11-040 are in clinical/preclinical development. The company also commercializes reagents (HCW9206, HCW9201) supporting CAR-T and NK-cell therapy manufacturing.Explore more
HCW Biologics Org Chart
Show More
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is HCW Biologics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Website visits: Recent activity has been detected on your website
Congratulate Masked Content for being promoted to Masked Content at HCW Biologics
Check if HCW Biologics has recently received funding, and reach out quickly before it becomes old news!
Product Launch: Get notified when HCW Biologics launches new products
Earning: See what the market has to say on HCW Biologics recently announced quarterly report
Funding: Get notified immidiatlly once HCW Biologics has new funding data
HCW Biologics, which may be a good buyer, showed buying intent in Masked Content Topic
Click to see if HCW Biologics had a recent Job posting/layoffs
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check out if HCW Biologics is spiking on competitors!
Recommended Actions
Find VP level buyers at HCW Biologics
Find 2 more new buyers
Compare Similar Companies to HCW Biologics
Compare insights from companies similar to HCW Biologics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
HCW Biologics is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
HCW Biologics is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about HCW Biologics.
HCW Biologics financials insights
Gather financial insights about HCW Biologics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2020
Debt
$350K
2023
Debt
$26.3M
2026
Stock/Share Issuance
$4M
HCW Biologics Tech Stack
A closer look at the technologies used by HCW Biologics
Most Recent Scoops
Partnership
HCW Biologics has entered into a licensing agreement with Trimmune for the in vivo use of HCW11-006, effective as of March 2026. Under the terms of the agreement, HCW Biologics retains an option to reclaim rights for the American market following Trimmune's completion of a phase I study in China, exercisable at no cost and on a royalty-free basis.
Partnership
Project
HCW Biologics has selected HCW11-040 as a best-in-class molecule for clinical development, noting that in animal trials and laboratory studies this molecule has outperformed KEYTRUDA by more effectively expanding and activating memory T-cells and progenitor exhausted T-cells (TPEX). HCW11-040 is derived from the genetic form of KEYTRUDA and is considered a potential front-line candidate within HCW Biologics's portfolio of over 50 molecules.
Medical Research, Clinical Operations
Project
HCW Biologics has IND-enabling studies underway for HCW11-040, with completion expected in H2 2027, at which point HCW Biologics plans to immediately file an IND application to evaluate HCW11-040 in bronchopulmonary dysplasia (BPD).
Medical Research, Pharmaceuticals
Funding
Funding
Person-Based
HCW Biologics News & Media
HCW Biologics Inc. Announces Pricing of $1.6 Million Private Placement Offering
MIRAMAR, Fla., July 29, 2026 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”), (NASDAQ: HCWB), a clinical-stage biopharmaceutical company developing transformative fusion immunotherapeutics to treat autoimmune diseases, cancer and senescence-associated dysplasia, today announced the pricing of its $1.6 million private placement offering (the “Offering”) with a group of investors, including officers, directors and an existing stockholder of the Company, (each, and “InvestHCW Biologics Reaches Milestones for Its Proprietary Tetravalent Second-Generation T-Cell Engager Program On Track To Initiate Clinical Trials in First Half 2027
Company requested Type B pre-IND meeting with U.S. FDA to discuss development and regulatory strategy for its investigational tetravalent T-cell engager, HCW11-018bHCW Biologics Regained Compliance with Bid Price Rule Per Nasdaq Compliance Letter
Company now compliant with all continued listing rules for Nasdaq Company now compliant with all continued listing rules for NasdaqHCW Biologics Announces 1-for-6 Reverse Stock Split Effective on June 30, 2026
Company completed 28 consecutive trading days above $1.00 per share on June 25, 2026
Read more news
Top Business Services Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding HCW Biologics
Sign Up For FreeTo access detailed company insights
HCW Biologics is a clinical-stage biopharmaceutical company developing fusion immunotherapeutics for chronic inflammation-driven diseases, including autoimmune disorders, cancer, and senescence-associated dysplasia. Led by Founder/CEO Dr. Hing C. Wong (who previously developed FDA-approved Anktiva®, sold to ImmunityBio for $1.0B), lead candidates H... Read More
